Labcorp Collaborates With Roche To Bring Fully Automated Mass Spectrometry To U.S. Clinical Labs

First U.S. commercial agreement delivers next-generation technology for faster, more accurate diagnostics

Labcorp a global leader of innovative and comprehensive laboratory services, announced today that it is the first U.S. commercial laboratory with an agreement to implement Roche’s cobas Mass Spec solution. This collaboration introduces fully automated mass spectrometry into routine clinical practice—accelerating turnaround times, improving accuracy, and expanding access to advanced diagnostics for patients and providers nationwide.

“Labcorp is committed to advancing diagnostic science through transformative technologies,” said Marcia Eisenberg, Ph.D., Labcorp’s chief scientific officer. “Integrating Roche’s automated mass spectrometry solution will enable us to deliver greater accuracy and efficiency for critical tests that guide treatment decisions and improve patient outcomes.”

Understanding Mass Spectrometry
Mass spectrometry is a powerful technique for identifying and measuring molecules based on their weight and electrical charge. Its selectivity, sensitivity and accuracy make it essential for complex tests such as steroid hormone analysis, vitamin D measurement, and therapeutic drug monitoring—where even small variations can impact treatment decisions.

Historically, mass spectrometry required specialized expertise and manual processes, limiting its use in routine clinical labs. Roche’s cobas Mass Spec solution changes that by automating the entire workflow—from sample preparation to result interpretation—making these critical tests faster, more reliable, and more widely accessible.

Key Features of Roche’s cobas Mass Spec Solution

• Fully Automated Workflow – Eliminates manual steps, reducing complexity and turnaround times
• Broad Test Menu – Approximately 60 assays to be introduced over time
• Integrated Platform – Designed for future integration with clinical chemistry and immunochemistry analyzers

“This collaboration reflects our shared vision to make advanced diagnostics widely accessible,” said Brad Moore, President and CEO, Roche Diagnostics North America. “Together, we are setting a new benchmark for accuracy, reliability and efficiency in patient care.”

The cobas Mass Spec Solution will first be deployed at Labcorp’s Burlington, North Carolina laboratory, with launch expected in the first quarter of 2026, followed by expansion to additional Labcorp locations. This agreement builds on Labcorp’s long-standing collaboration with Roche and underscores its commitment to delivering innovative solutions across its Diagnostics and Biopharma Laboratory Services (BLS) business segments.

About Labcorp
Labcorp is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. For more information, visit www.labcorp.com.